A Study of IBI351 in Healthy Subjects
An Open-label, 2-cycle Clinical Study to Evaluate the Drug Interaction Between Itraconazole or Dextromethorphan and IBI351 in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Haiyan Zhu
- Phone Number: 0512-69566088
- Email: haiyan.zhu@innoventbio.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China
- The First Affiliated Hospital of Suzhou University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the trial, and be able to complete the study according to the requirements of the trial protocol.
- Healthy male subjects aged 18 to 45 years (including both ends) at the time of signing informed consent.
- Body weight is not less than 50 kg, and body mass index (BMI) is in the range of 19 ~ 26 kg/m2 (including both ends).
- Physical examination, vital signs, routine laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function), thyroid function, 12-lead electrocardiogram, chest CT, abdominal ultrasound (hepatobiliary, pancreatic, spleen and kidney), echocardiography (only applicable to Cohort 1 subjects) showed no abnormalities; or abnormal test results but judged as normal or clinically insignificant by the investigator.
Exclusion Criteria:
- have taken any products containing alcohol or have a positive alcohol breath test (≥ 20 mg/100 ml) within 24 hours before taking study medication.
- hepatitis B surface antigen HBsAg positive.
- hepatitis C virus antibody positive.
- positive AIDS antigen/antibody or Treponema pallidum antibody.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: IBI351+ itraconazole
Enrolled subjects were treated with IBI351 on an empty stomach on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 3 to Day 6. IBI351 and itraconazole were administered simultaneously on an empty stomach on Day 7. On Day 8, itraconazole was orally administered once after a standard meal.
|
Itraconazole was administered orally
IBI351 was administered orally
|
|
Other: IBI351+ dextromethorphan
Enrolled subjects were orally administered dextromethorphan on an empty stomach on Day 1. IBI351 and dextromethorphan were orally administered simultaneously on an empty stomach on Day 3, followed by IBI351 12 hours later.
|
IBI351 was administered orally
Dextromethorphan was administered orally
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
maximum concentrations (Cmax ) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
maximum concentrations (Cmax ) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
area under the curve from time 0 to infinity(AUC0-inf) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
area under the curve from time 0 to infinity(AUC0-inf) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time-to-maximum concentration (Tmax) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
half-life (t1/2) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
area under the curve from time 0 to time (AUC0-t) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
apparent clearance (CL/F) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
apparent volume of distribution(Vz/F) for IBI351
Time Frame: approximately 10 days
|
approximately 10 days
|
|
time-to-maximum concentration (Tmax) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
half-life (t1/2) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
area under the curve from time 0 to time (AUC0-t) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
apparent clearance (CL/F) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
apparent volume of distribution(Vz/F) for dextromethorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
area under the curve for dextrorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
maximum concentrations (Cmax ) for dextrorphan
Time Frame: approximately 10 days
|
approximately 10 days
|
|
number of participants with abnormal hematology tests
Time Frame: approximately 10 days
|
approximately 10 days
|
|
number of participants with abnormal chemistry parameters
Time Frame: approximately 10 days
|
approximately 10 days
|
|
number of participants with abnormal vital signs
Time Frame: approximately 10 days
|
approximately 10 days
|
|
number of participants with abnormal physical examination findings
Time Frame: approximately 10 days
|
approximately 10 days
|
|
number of participants with abnormal ECG readings
Time Frame: approximately 10 days
|
approximately 10 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Respiratory System Agents
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antitussive Agents
- 14-alpha Demethylase Inhibitors
- Dextromethorphan
- Itraconazole
Other Study ID Numbers
Other Study ID Numbers
- CIBI351P003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.